Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
- Amsterdam UMC
- SciLifeLab
- Amsterdam UMC, location VUmc
- Autonomous University of Madrid (Universidad Autónoma de Madrid)
- German Cancer Research Center in the Helmholtz Association (DKFZ)
- Hannover Medical School
- Hannover Medical School •
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- Institute for Ophthalmic Research
- International Centre for Translational Eye Research / Institute of Physical Chemistry, Polish Academy of Sciences
- KU LEUVEN
- Sanquin Blood Supply Foundation (Sanquin)
- Umeå University
- University of Gdansk
- University of Lleida
- University of Warwick
- Łukasiewicz Research Network - Krakow Institute of Technology
- 7 more »
- « less
-
Field
-
candidate will benefit from a network of European experts in different fields (gene therapy, pharmacology, bioinformatics, disease modeling, imaging) and will have the possibility to visit other labs in
-
of newborn screening and the first gene therapies, affected children can increasingly be identified and treated before symptom onset. However, minimally invasive biomarkers are still needed to support early
-
the Graduate School of the Cyprus Institute of Neurology and Genetics. You will pursue a PhD degree in Neuroscience. You will contribute to the development and evaluation of gene therapy approaches for PMLD1
-
mutations in the Survival Motor Neuron 1 (SMN1) gene, resulting in reduced levels of SMN protein. Because patients lack a functional copy of SMN1, SMN protein production relies on the SMN2 gene, which
-
more than 50% of breast cancer cases. Current treatment strategies involve chemotherapy, endocrine therapy and, subsequently, targeted therapies. However, treatment resistance frequently develops, while
-
Development Fund. The aim of ICCVS has been comprehensive research into development of novel diagnostic and prognostic markers and personalized anti-cancer therapies and vaccines, followed by
-
in vivo gene therapy, with >200 clinical trials and six products approved in Europe. However, rAAV manufacturing remains inefficient, and manufacturing thus proposes a significant bottleneck for safe
-
of treatment are a significant factor inhibiting the use of High Flow Nasal Cannula Therapy among some clinicians. Using data from clinical collaborators around the world, this project will develop a user
-
shaping the future of regenerative medicine and Advanced Therapy Medicinal Products (ATMPs)? ATMPs are transforming healthcare by harnessing the power of cells, genes, and engineered tissues to repair
-
to develop a novel universal therapy for maintaining hemostasis in patients at risk for bleeding. Objectives Computational de novo design of VHH and scFv binders to blood coagulation factors such as factor Xa